Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Drais Pharmaceuticals and Unibioscreen have entered into a global agreement to develop and commercialize UNBS 5162, one of Unibioscreen's investigational drug and potential breakthrough treatments for cancer.
Subscribe to our email newsletter
Under the terms of the agreement, Unibioscreen will receive upfront, development and regulatory milestones payments up to $31 million, in addition to commercial milestone payments. The license grants exclusive rights to Drais to develop and commercialize UNBS 5162 worldwide.
UNBS 5162 is a novel anti-cancer naphthalimide discovered, patented and developed by Unibioscreen. In preclinical studies, UNBS 5162 has shown antitumor activity in several cancer models and is currently in a Phase I trial in the US.
Christiane Verhaegen, CEO and CFO of Unibioscreen, said: “Unibioscreen’s deal with Drais is a key milestone for both the development of the drug candidate and for the company as it provides validation of Unibioscreen’s promising pipeline of potential cancer treatments in addition to monetary benefits. We are confident that Drais’s experienced team will maximize the progression of UNBS 5162 and believe this agreement will provide excellent value for both partners.”